Clinical Trial Update: Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Cross Match Living Donor Kidney Transplant [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports Phase 1/2 results evaluating adding the complement inhibitor eculizumab to standard treatment in recipients of positive cross…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• SOLIRIS (eculizumab)

Snippet

Sponsor: Mark Stegall | Conditions: Kidney Transplant | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-06-26